Testing ruxolitinib plus duvelisib for relapsed T-cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This Phase 1 study tests how safe and effective ruxolitinib plus duvelisib are in adults with certain types of mature T-cell lymphomas. You may be considered if your lymphoma has come back or worsened despite prior treatment, and the study checks whether this pill combination can help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have mature T-cell lymphoma confirmed by biopsy/pathology at the study site
- You’re age 18 or older
- Your ability to do daily activities is limited at most (ECOG 0–2)
- Your blood counts and organ tests meet minimum levels (neutrophils, platelets, kidneys, and liver)
- You have measurable lymphoma (or other signs they can track), and you can swallow pills
- You can follow pregnancy prevention rules during the study and for 3 months after
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests ruxolitinib, a targeted medicine, to improve outcomes in T-cell large granular lymphocytic leukemia (T-LGLL). It is for people whose disease is causing symptoms or who have already tried other treatment, with specific blood, infection, and medication requirements.
This study tests two oral drugs—duvelisib and venetoclax—to see if together they can help people with a type of lymphoma called peripheral T-cell lymphoma (PTCL) that has not responded to at least two prior treatments.
This trial tests whether taking ruxolitinib after a stem cell transplant can help prevent T-cell lymphoma from coming back. It is for patients whose lymphoma is in remission (partial or complete) after their transplant.
This trial studies ruxolitinib, a medicine that affects immune signaling, in people whose T-cell or NK-cell lymphoma has returned or hasn’t responded to treatment. It may help shrink lymphoma and improve symptoms after other therapies.
This trial tests a new drug, duvelisib, against two standard chemotherapy drugs (gemcitabine or bendamustine) for people with T-cell lymphoma that has come back or not responded to treatment. Duvelisib is a targeted therapy that may work differently than chemotherapy.
This early-phase trial tests whether a combination medicine (ruxolitinib plus paclitaxel) can treat diffuse large B-cell lymphoma that has come back or did not respond to prior treatment. It may help by shrinking the lymphoma and improving control of the disease.
Hear when a new T-cell Prolymphocytic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.